Status:
RECRUITING
Genetic Susceptibility in MAlignant Pleural Mesothelioma: Clinical Implication of GermliNE VariaTionS
Lead Sponsor:
Fondazione IRCCS Policlinico San Matteo di Pavia
Collaborating Sponsors:
Istituti Clinici Scientifici Maugeri di Pavia
Conditions:
Mesothelioma, Malignant Pleural
Eligibility:
All Genders
18+ years
Brief Summary
Malignant pleural mesothelioma (MPM) is a rare and aggressive neoplasm of the pleural mesothelium, mainly associated to asbestos exposure, still lacking effective therapies. Asbestos is a not-mutagen...
Detailed Description
Malignant pleural mesothelioma (MPM) is a rare and aggressive neoplasm of the pleural mesothelium, mainly associated to asbestos exposure, still lacking effective therapies. Incidence rates in Europe ...
Eligibility Criteria
Inclusion
- Inclusion Criteria Cohort A:
- Patient with a documented diagnosis of MPM (any disease stage and independently from chemo line treatment)
- Age ≥ 18 years (there is no upper age limit).
- Patient who gives their informed consent to participate in the study
- Exclusion Criteria Cohort A:
- No exclusion criteria
- Inclusion Criteria Cohort B:
- Former asbestos exposed healthy subjects
- Age ≥ 18 years (there is no upper age limit).
- Subject who gives their informed consent to participate in the study
- Exclusion Criteria Cohort B:
- No exclusion criteria
Exclusion
Key Trial Info
Start Date :
June 15 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT06886672
Start Date
June 15 2023
End Date
December 31 2025
Last Update
March 20 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Fondazione IRCCS Policlinico San Matteo
Pavia, Pavia, Italy, 27100
2
IRCCS Istituti Clinici Maugeri, Medicina del Lavoro
Pavia, Pavia, Italy, 27100